Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid

Hepatology

Volumn 31, Issue 2, 2000, Pages 318-323

  Angulo, Paul ^a   Jorgensen, Roberta A ^a   Keach, Jill C ^a   Dickson, E Rolland ^a   Smith, Coleman ^b   Lindor, Keith D ^a  

^a MAYO CLINIC   (United States)

^b Minnesota Gastroenterology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; BILIRUBIN; BUDESONIDE; URSODEOXYCHOLIC ACID;

ADULT; AGED; ARTICLE; BILIRUBIN BLOOD LEVEL; BONE ATROPHY; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVITY; FEMALE; HUMAN; HYPERGLYCEMIA; MALE; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL;

EID: 0033966156     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510310209     Document Type: Article

References (11)

1. Poupon RE, Balkau B, Eschwege E, Poupon R, and the UDCA-PBC study group. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med 1991;324:1548-1554.
2. Lindor KD, Dickson ER, Baldus WP, Jorgensen RA, Ludwig J, Murtaugh PA, Harrison JM, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994;106:1284-1290.
3. Heathcote EJ, Cauch-Dudek K, Walker V, Bailey RJ, Blendis LM, Ghent CN, Michieletti P, et al. The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. HEPATOLOGY 1994;19:1149-1156.
4. Combes B, Carithers RL, Maddrey WC, Lin D, McDonald MF, Wheeler DE, Eigenbrodt EH, et al. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. HEPATOLOGY 1995;22:759-766.
5. Angulo P, Batts KP, Therneau TM, Jorgensen RA, Dickson ER, Lindor KD. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. HEPATOLOGY 1999;29:644-647.
6. Poupon RE, Poupon R, Balkau B, and the UDCA-PBC study group. Ursodiol for the long-term treatment of primary biliary cirrhosis. N Engl J Med 1994;330:1342-1347.
7. Lindor KD, Therneau TM, Jorgensen RA, Malinchoc M, Dickson ER. Effects of ursodeoxycholic acid on survival of patients with primary biliary cirrhosis. Gastroenterology 1996;110:1515-1518.
8. Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997;113:884-890.
9. Emond M, Carithers RL Jr, Luketic VA, Peters M, Zetterman RK, Garcia-Tsao G, Munoz SJ, et al. Does ursodeoxycholic acid improve survival in patients with primary biliary cirrhosis? Comparison of outcome in the U.S multicenter trial to expected survival using the Mayo Clinic prognostic model [Abstract]. HEPATOLOGY 1996;168A.
10. Angulo P, Dickson ER, Therneau TM, Jorgensen RA, Smith C, DeSotel CK, Lange SM, et al. Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial. J Hepatol 1999;30:830-835.
11. Angulo P, Lindor KD, Therneau TM, Jorgensen RA, Malinchoc M, Kamath PK, Dickson ER. Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid. Liver 1999;19:115-121.